Male pill on horizon

A reversible way of stopping sperm cells being ejaculated has been identified in mice. The research could pave the way for the development of a male
contraceptive pill.

The
researchers at Monash
University, Australia, and the University
of Leicester, UK, engineered male mice to lack two proteins -
P2X1-purinoreceptors and alpha1A-adrenoreceptors. Together these proteins
enable sperm cells to travel from the testes to the penis through a muscular
tube called the vas deferens. Deletion of these proteins means that sperm
remain in the testes upon ejaculation.

Study
lead author Dr
Sabatino Ventura of Monash University told the BBC: 'The sperm
stay in the storage site so when the mice ejaculate there's no sperm and they
are infertile'.

When the
genetically-modified male mice were allowed to mate with female mice, no
pregnancies resulted, meaning they were infertile. However, the male
mice still showed normal sexual behaviour, which is an important requirement
for a male contraceptive. The males also had normal sperm and were able to
father offspring after their sperm was extracted and used to fertilise eggs in vitro.

Currently,
there is no male contraceptive pill available and studies to date have focused on
producing dysfunctional sperm that are unable to fertilise the egg. However,
these methods can have serious side effects such as long term effects on
fertility and sexual function. An advantage of the new approach is that sperm remain
functional while sperm transport is blocked.

The next
challenge will be to find a pair of drugs that can block these two proteins in
humans. Adrenoreceptor-blocking drugs are already used to treat prostate hyperplasia
- a benign swelling of the prostate gland. However, a purinoreceptor blocking
drug has yet to be developed and this process could take years.

The two
proteins that were targeted also have a role in controlling blood vessels so blocking
them could have side effects on blood pressure or heart rate. Researchers only
observed a very slight drop in blood pressure in the engineered mice but this
would need to be carefully monitored if this approach was tested in humans.

Dr Allan Pacey,
senior lecturer in andrology at the University of Sheffield, told the BBC: 'It's
a good idea; they need to get on with it and see what it does in people'.

The study was published in the journal Proceedings of the National
Academy of Sciences.